By Fineline Cube Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that Phase I/II clinical trials are underway for HP‑002, a Class 1 innovative chemical drug independently developed by the company, for the treatment of relapsed or refractory B‑cell non‑Hodgkin lymphoma (B‑NHL). The first patient dosing was recently completed, marking the program’s entry into clinical evaluation.
Regulatory & Clinical Milestone
| Item | Detail |
|---|---|
| Developer | Easton Pharmaceutical Co., Ltd. (SHA: 688513), Chengdu |
| Product | HP‑002 (Class 1 innovative chemical drug) |
| Stage | Phase I/II clinical trials underway; first patient dosed |
| Indication | Relapsed or refractory B‑cell non‑Hodgkin lymphoma (B‑NHL) |
| Announcement Date | 13 Aug 2026 |
| Next Steps | Dose escalation and preliminary efficacy assessment in the Phase I/II study |
Drug Profile & Mechanism of Action
- Molecule: HP‑002, a next‑generation, brain‑penetrant PROTAC (proteolysis targeting chimera) molecule
- Target: Bruton’s tyrosine kinase (BTK), a key driver of B‑cell malignancies
- Mechanism: As a PROTAC degrader, HP‑002 is designed to eliminate BTK protein rather than merely inhibit it — a strategy intended to overcome resistance mutations that limit existing covalent and non‑covalent BTK inhibitors
- Differentiation: Combines BTK degradation with blood‑brain barrier penetration, addressing CNS involvement in B‑NHL where current therapies often fail
Preclinical Evidence
| Element | Result (HP‑002) |
|---|---|
| Anti‑Proliferative Activity | Potent activity against various BTK‑mutant cell lines |
| In Vitro Profile | Best‑in‑class activity against multiple BTK mutations |
| In Vivo Efficacy | Significantly outperformed clinical‑stage control molecule NX‑5948 (Nurix Therapeutics) in two distinct animal models |
| Pharmacokinetics | Superior oral bioavailability and blood‑brain barrier penetration vs. control |
Preclinical studies demonstrated that HP‑002 exhibits best‑in‑class in vitro activity against multiple BTK mutations. In two distinct in vivo efficacy animal models, its activity significantly outperformed NX‑5948, the clinical‑stage BTK degrader from Nurix Therapeutics, while pharmacokinetic evaluations showed superior oral bioavailability and blood‑brain barrier penetration.
Market Impact & Outlook
- Resistance‑Driven Unmet Need: Patients with B‑NHL who relapse after covalent BTK inhibitors such as ibrutinib often carry resistance mutations; BTK degraders are designed to address precisely this population, making the segment one of the most closely watched in hematologic oncology.
- Competitive Benchmarking: Head‑to‑head preclinical superiority over NX‑5948, the leading clinical‑stage BTK PROTAC, positions HP‑002 as a potentially differentiated entrant in the BTK degrader race.
- CNS Opportunity: Brain penetrance is rare among BTK‑targeted therapies and could open treatment options for patients with CNS involvement — a significant differentiator if confirmed clinically.
- Platform Validation: The first‑patient dosing of a proprietary Class 1 PROTAC validates Easton Pharmaceutical’s targeted protein degradation platform and extends Chengdu’s growing footprint in innovative oncology drug development.
Forward-Looking Statements
This brief contains forward‑looking statements regarding clinical trial progress, efficacy outcomes, and commercial potential for HP‑002. Actual results may differ due to risks including Phase I/II safety and efficacy data, regulatory decisions, and competitive dynamics in the BTK degrader market.-Fineline Info & Tech